| Biomarker ID | 223 |
| PMID | 17932343 |
| Year | 2007 |
| Biomarker | MMP-3 (Matrix Metalloproteinase-3) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR - 0.68 |
| Effect on Pathways | Pathways Include:- EGFR transactivation by gastrin,Post-translational regulation of adherens junction stability and disassembly,Activation of matrix metalloproteinases,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling, Matrix metalloproteinases |
| Experiment | Cancerous Vs Normal Patients |
| Type of Biomarker | Diagnostic |
| Cohort | 126 patients with Prostate Cancer were identified from SABORT cohort and correspondingly 127 age matched cohorts were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.583 |
| Accuracy | NA |
| Level Of Significance | p=0.01 |
| Method Used | LabMAP Technology |
| Clinical | No |
| Remarks | A total panel of 54 markers was evaluated to check whether they could differentiate between cases (Prostate Cancer) and age matched controls. They panel could not differentiate between the two. But the given markers were found differentially expressed between the two. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MMP3 |